Curis (CRIS) Assets Average (2011 - 2026)
Curis' (CRIS) quarterly Assets Average came in at $24.8 million in Q1 2026, down 38.39% YoY from $40.3 million in Q1 2025, and up 4.3% on a QoQ basis from $23.8 million in Q4 2025.
Curis (CRIS) Assets Average (2011 - 2026) Analysis & Trends
Curis (CRIS) has 16 years of Assets Average data on file, last reported at $24.8 million in Q1 2026.
- Quarterly Assets Average fell 38.39% year-over-year to $24.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.8 million (down 38.39% YoY) and the FY2025 annual result came in at $30.6 million, down 48.35% from the prior year.
- Assets Average rose to $24.8 million in Q1 2026, from $23.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $151.5 million in Q1 2022 to a low of $23.8 million in Q4 2025.
- A 5-year average of $73.9 million and a median of $69.7 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average fell 23.27% — and 2024, when it slumped 49.93%.
- Tracing CRIS's Assets Average over 5 years: stood at $115.9 million in 2022, then fell by 27.81% to $83.6 million in 2023, then sank by 49.93% to $41.9 million in 2024, then slumped by 43.15% to $23.8 million in 2025, then climbed by 4.3% to $24.8 million in 2026.
- The last three Assets Average figures came in at $24.8 million (Q1 2026), $23.8 million (Q4 2025), and $28.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Curis | 3.44 Mn | -2.18 Mn | - | 24.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.83 Mn |
| Dec 31, 2025 | 23.80 Mn |
| Sep 30, 2025 | 28.44 Mn |
| Jun 30, 2025 | 34.28 Mn |
| Mar 31, 2025 | 40.30 Mn |
| Dec 31, 2024 | 41.87 Mn |
| Sep 30, 2024 | 46.44 Mn |
| Jun 30, 2024 | 56.22 Mn |
| Mar 31, 2024 | 69.65 Mn |
| Dec 31, 2023 | 83.63 Mn |
| Sep 30, 2023 | 87.14 Mn |
| Jun 30, 2023 | 89.43 Mn |
| Mar 31, 2023 | 101.70 Mn |
| Dec 31, 2022 | 115.85 Mn |
| Sep 30, 2022 | 125.84 Mn |
| Jun 30, 2022 | 134.79 Mn |
| Mar 31, 2022 | 151.52 Mn |
| Dec 31, 2021 | 167.19 Mn |
| Sep 30, 2021 | 176.64 Mn |
| Jun 30, 2021 | 185.89 Mn |